Skip to main
GPCR

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics is a clinical-stage biopharmaceutical company with a strong focus on developing small molecule therapeutics for chronic diseases. The recent initiation of Phase 3 trials and upcoming readouts for multiple Phase 2 trials show promising results for the company's novel technology platform. While there are risks involved in the development process, the company's solid financials and potential for commercial success suggest a positive outlook for investors in the long term.

Bears say

Structure Therapeutics is facing several hurdles as they develop their novel oral small-molecule therapeutics, including the need for Phase 3 data to confirm their potential efficacy and tolerability claims, potential challenges in differentiation from competitors' products, and the importance of demonstrating absolute GI burden below certain profiles in longer-term trials. Additionally, the recent breakthrough data for aleniglipron may lower confidence in their penetration assumptions, leading to a reduced price target for the company. However, the data also validates Structure's capabilities in oral small molecule development and GPCR targeting, increasing confidence in their ability to build an oral metabolic franchise. Furthermore, the potential for an all-oral GLP-1/amylin combination could significantly improve patient access and adherence, providing a competitive advantage in the market.

GPCR has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Strong Buy based on their latest research and market trends.

According to 10 analysts, GPCR has a Strong Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.